

《肝癌抗癌藥物治療指引》

115 年版與上一版差異

114 年版 修訂日 114/01/07	115 年版 修訂日 114/12/09
First-line systemic therapy	First-line systemic therapy ◎ 新增 Nivolumab + Ipilimumab followed by Nivolumab
Subsequent-line therapy if disease progression	Subsequent-line therapy if disease progression ◎ 新增 • Cabozantinib • Atezolizumab + Bevacizumab • Tremelimumab + Durvalumab • Durvalumab • Tislelizumab-jsgr

《肝癌抗癌藥物治療指引》

Hepatocellular Carcinoma

First-line systemic therapy

Sorafenib (Child-Pugh Class A [category 1] or B7)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Sorafenib	400mg PO BID				1, 2

Lenvatinib (Child-Pugh Class A only)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Lenvatinib	8 or 12mg* PO QD				5

*8 mg/day for BW <60 kg; 12 mg/day for BW ≥ 60 kg

Atezolizumab + Bevacizumab (Child-Pugh Class A only)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Atezolizumab	1200 mg	60-90 mins	d1	Q3W		8
Bevacizumab	15 mg/kg	60-90 mins	d1	Q3W		

Tremelimumab + Durvalumab

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Tremelimumab	300 mg	1 hr	d1	Single dose		11
Durvalumab	1500 mg	1 hr	d1	Q3W		

Durvalumab

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Durvalumab	1500 mg	60 mins	d1	Q4W		11

Pembrolizumab

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W		12

Tislelizumab-jsgr

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Tislelizumab-jsgr	200 mg	≥ 90 → 60 mins	d1	Q3W		15

Nivolumab + Ipilimumab

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Nivolumab	240 mg	≥ 30 mins	d1	Q2W		14
Ipilimumab	1 mg/kg	≥ 30 mins	d1	Q6W		

Nivolumab + Ipilimumab followed by Nivolumab

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Nivolumab	1 mg/kg	≥ 30 mins	d1	Q3W		17
Ipilimumab	3 mg/kg	≥ 30 mins	d1	Q3W		
Followed by Nivolumab	480 mg	≥ 30 mins	d1	Q4W		

Subsequent-line therapy if disease progression

Regorafenib (Child-Pugh Class A only [category 1])

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Regorafenib	160mg PO QD	d1-21	Q4W		3

Cabozantinib (Child-Pugh Class A only [category 1])

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Cabozantinib	60mg PO QD				16

Atezolizumab + Bevacizumab

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Atezolizumab	1200 mg	60-90 mins	d1	Q3W		8
Bevacizumab	15 mg/kg	60-90 mins	d1	Q3W		

Tremelimumab + Durvalumab

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Tremelimumab	300 mg	1 hr	d1	Single dose		11
Durvalumab	1500 mg	1 hr	d1	Q3W		

Nivolumab (Child-Pugh Class A or B7 only)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Nivolumab	3 mg/kg	≥ 30 mins	d1	Q2W		4

Ramucirumab (AFP ≥ 400 mg/mL only [category 1])

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Ramucirumab	8 mg/kg	1 hr	d1	Q2W		6

Durvalumab

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Durvalumab	1500 mg	1 hr	d1	Q4W		11

Pembrolizumab

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	up to 35	7

Tislelizumab-jsgr

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Tislelizumab-jsgr	200 mg	$\geq 90 \rightarrow 60$ mins	d1	Q3W		15

Lenvatinib

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Lenvatinib	8 or 12* mg/day PO		d1			5

*8 mg/day for BW <60 kg; 12 mg/day for BW ≥ 60 kg

Nivolumab + Ipilimumab

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Nivolumab	1 mg/kg	≥ 30 mins	d1	Q3W	4	9
Ipilimumab	3 mg/kg	≥ 30 mins	d1	Q3W	4	

Sorafenib

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Sorafenib	400mg PO BID				10

參考文獻

1. Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. New Engl J Med 2008;359(4):378-390.
2. Cheng A, Kang Y, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
3. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.
4. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-2502.
5. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-1173.

6. Zhu AX, Kang YK, Yen CJ, et al. REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. *J Clin Oncol* 2018;36:4003.
7. Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. *Lancet Oncol.* 2018 Jul;19(7):940-952.
8. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. *N Engl J Med* 2020;382:1894-1905.
9. Yau T, Park JW, Finn RS, et al. CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma. *Ann Oncol* 2019 Oct;30 Suppl 5:v874-v87.
10. Tomonari T, Sato Y, et al. Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma. *JGH Open* 2020;4:1135–1139.
11. Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA [abstract]. *J Clin Oncol* 2022;40:Abstract 379.
12. van Laethem JL, Borbath I, Karwal M, et al. Updated results for pembrolizumab (pembro) monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC) in the phase II KEYNOTE-224 study [abstract]. *Ann Oncol* 2021;32:Abstract 933P.
13. D'Alessio A, Fulgenzi CAM, Nishida N, et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. *Hepatology* 2022;76:1000-1012.
14. Schenker M, Burotto M, Richardet M, et al. CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden [abstract]. *Cancer Res* 2022;82:Abstract CT022.

15. Qin S, Kudo M, Meyer T, et al. Tislelizumab vs sorafenib as first-Line treatment for unresectable hepatocellular carcinoma: A phase 3 randomized clinical trial. JAMA Oncol 2023;9:1651-1659.
16. Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018 Jul 5;379(1):54-63.
17. Yau T, Galle PR, Decaens T, et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet. 2025;405(10492):1851-1864.